Tuning payload delivery in tumour cylindroids using gold nanoparticles.
Nanoparticles have great potential as controllable drug delivery vehicles because of their size and modular functionality. Timing and location are important parameters when optimizing nanoparticles for delivery of chemotherapeutics. Here, we show that gold nanoparticles carrying either fluorescein or doxorubicin molecules move and localize differently in an in vitro three-dimensional model of tumour tissue, depending on whether the nanoparticles are positively or negatively charged. Fluorescence microscopy and mathematical modelling show that uptake, not diffusion, is the dominant mechanism in particle delivery. Our results indicate that positive particles may be more effective for drug delivery because they are taken up to a greater extent by proliferating cells. Negative particles, which diffuse more quickly, may perform better when delivering drugs deep into tissues. An understanding of how surface charge can control tissue penetration and drug release may overcome some of the current limitations in drug delivery.
Kim
Byoungjin
B
Department of Chemical Engineering, University of Massachusetts, Amherst, Massachusetts 01003-9303, USA.
Han
Gang
G
Toley
Bhushan J
BJ
Kim
Chae-Kyu
CK
Rotello
Vincent M
VM
Forbes
Neil S
NS
D000838:Anions / Q000737:chemistry / Q000493:pharmacokinetics; D002412:Cations / Q000737:chemistry / Q000493:pharmacokinetics; D045744:Cell Line, Tumor; D004317:Doxorubicin / Q000493:pharmacokinetics; D016503:Drug Delivery Systems / Q000379:methods*; D019793:Fluorescein / Q000493:pharmacokinetics; D006046:Gold / Q000737:chemistry* / Q000493:pharmacokinetics; D006801:Humans; D016018:Least-Squares Analysis; D053768:Metal Nanoparticles / Q000737:chemistry*; D008856:Microscopy, Fluorescence; D008954:Models, Biological; D009369:Neoplasms; D019047:Phantoms, Imaging
D000838:Anions; D002412:Cations; D006046:Gold; D004317:Doxorubicin; D019793:Fluorescein
Clin Cancer Res. 1999 Jul;5(7):1703-7
10430072
Glia. 2000 Jun;30(4):329-41
10797613
Anal Chem. 1995 Dec 1;67(23):4261-8
8633771
Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9138-43
12886020
Cancer Res. 1987 Jun 15;47(12):3039-51
3555767
Biochemistry. 1982 Nov 23;21(24):6188-93
6217835
Org Lett. 2005 Dec 8;7(25):5685-8
16321022
J Am Chem Soc. 2005 Sep 21;127(37):12873-81
16159281
Science. 1988 Apr 8;240(4849):177-84
2451290
Cancer Res. 1990 Aug 1;50(15):4478-84
2369726
Nano Lett. 2007 Jun;7(6):1542-50
17465586
Drug Deliv. 2004 May-Jun;11(3):169-83
15204636
Cancer Res. 2006 Jan 15;66(2):1033-9
16424039
Soft Matter. 2006 Feb 15;2(3):190-204
32646145
Biotechnol Bioeng. 2007 Apr 15;96(6):1167-82
17009333
Nat Med. 1997 Feb;3(2):177-82
9018236
Chem Biol Drug Des. 2006 Apr;67(4):297-304
16629827
Cancer Res. 1989 Dec 1;49(23):6449-65
2684393
J Cell Biol. 1984 Aug;99(2):639-47
6430915
Nat Rev Cancer. 2006 Aug;6(8):583-92
16862189
Br J Cancer. 1962 Jun;16:306-22
13899681
Bioconjug Chem. 2008 Jul;19(7):1342-5
18553895
J Am Chem Soc. 2006 Feb 1;128(4):1078-9
16433515
Science. 2006 May 19;312(5776):1027-30
16709779
Annu Rev Biomed Eng. 1999;1:241-63
11701489
Cancer Res. 1980 Nov;40(11):3956-65
7471046
Microvasc Res. 1991 Sep;42(2):160-78
1719353
Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4628-33
11274375
J Pathol Bacteriol. 1950 Jul;62(3):313-33
14784896
Cancer Res. 2007 Apr 1;67(7):3201-9
17409428
Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12349-54
8901584
Cancer Res. 2003 Sep 15;63(18):5970-7
14522924
Br J Cancer. 2002 May 20;86(10):1639-44
12085216
J Am Chem Soc. 2007 Sep 5;129(35):10747-53
17672456
J Natl Cancer Inst. 2007 Oct 3;99(19):1441-54
17895480
Biotechnol Bioeng. 2006 Jul 5;94(4):710-21
16470601
J Am Chem Soc. 2001 Aug 8;123(31):7626-9
11480984
Biophys J. 2002 Sep;83(3):1650-60
12202388
Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8782-8
16361566
Clin Chim Acta. 1998 Jul 28;275(2):175-84
9721075
Biotechnol Bioeng. 2008 Nov 1;101(4):797-810
18814293